Swiss bank, global wealth and markets player
A wave of AI-related IPOs from SpaceX, Anthropic and OpenAI is unfolding, with markets facing a flood of new stock. Retail demand remains strong for SpaceX, but analysts warn supply could overwhelm demand, pressuring prices and testing market resilience.
The Insolvency Service has disqualified Lex Greensill from directing UK companies for nine years after finding he breached his duties as a director; the action follows the 2021 collapse of Greensill Capital and related investigations.
Swiss voters have rejected the Swiss People’s Party initiative to cap the country’s population at 10 million by 2050, with roughly 55% voting against and 45% in favour. The measure would have forced stricter asylum and family-reunification rules once population hit 9.5 million and could have ended free movement with the EU if the 10 million limit were breached.
A wave of investment in AI infrastructure is reshaping manufacturing and tech stocks. Nvidia and its partners are expanding AI factory builds and chip supply, aiming to turn software-powered automation into lasting economic growth while policymakers grapple with export controls and energy costs.
Gold and silver have paused their retreat as hawkish central-bank signals and inflation fears weigh on the metals. Oil prices stay subdued, and markets eye key U.S. data on jobs and inflation to gauge the path of monetary policy. Yields on U.S. Treasuries have moved little on the final trading day of June. This update covers developments through July 1, 2026.
The world’s richest person has seen his fortune swing wildly after SpaceX’s IPO. SpaceX and Tesla shares have fallen amid a broader tech sell-off, eroding Musk’s trillionaire status. Despite volatility, he remains the wealthiest individual as markets reassess growth prospects in AI and tech.
Gold has fallen from its 2025 peak as higher real yields and a firmer dollar weigh on prices, with analysts noting divergent drivers behind safe-haven demand and new forecasts suggesting limited upside this year.
UBS reports 2025 global wealth rose 10.8%, fueled by stock markets and tech gains. The number of millionaires surged worldwide, led by the United States; median wealth fell in many markets, widening the rich-poor gap. Australia saw a rise in millionaires, though median wealth declined. The report highlights how assets and housing influence millionaire status and global inequality.
European regulators are preparing a package to deregulate and potentially cut capital backstops for banks, aiming to create pan-European lenders capable of competing with U.S. giants. The plan includes cutting Pillar 2 leverage add-ons, reducing capital buffers, easing reporting, and outlining a common deposit-insurance framework. The move follows similar U.S. and U.K. deregulation signals and is seen as a test of Europe’s capacity to finance large-scale strategic investments.
AMD has unveiled its Helios AI rack system at Advancing AI in San Francisco, promising higher throughput and lower cost per token. The system targets hyperscalers and data centers, with partnerships across Microsoft, Anthropic, OpenAI, and others. The move intensifies the race with Nvidia as AMD argues Helios delivers greater inference efficiency.
The U.S.-Israel conflict has heightened volatility in global markets, boosting LSEG’s trading and data businesses. UBS and other banks report strong Q2 results, while AI narratives continue to influence investor sentiment. Regulators review prime brokerage activity in London amid regional economic uncertainty.
The yen has lost about half the gains it made after a rare U.S.-Japan coordinated intervention two weeks ago, trading above ¥159 per dollar. Market forces — a wide U.S.-Japan yield gap, higher U.S. Treasury yields and costly energy imports — are continuing to push money into dollar assets and reassert the yen-funded carry trade.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.